GSK shares jump after landmark £1.68bn heartburn drug settlement
GSK's shares rose following a $2.2 billion settlement for Zantac lawsuits in the US. The settlement with 80,000 claimants alleging cancer risks was seen as a win for GSK, which will not impact its growth plans. Other drugmakers faced similar issues.